Cargando…
Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis
OBJECTIVES: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis. BACKGROUND: Delays in diagnosis of cardiac amyloidosis are common, usually resulting from nonspecific findings on clinical examination an...
Autores principales: | Zhang, Kathleen W., Miao, Jennifer, Mitchell, Joshua D., Alvarez-Cardona, Jose, Tomasek, Kelsey, Su, Yan Ru, Gordon, Mary, Cornell, R. Frank, Lenihan, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717591/ https://www.ncbi.nlm.nih.gov/pubmed/33283202 http://dx.doi.org/10.1016/j.jaccao.2020.01.006 |
Ejemplares similares
-
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2019) -
Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis
por: Ridouani, Fourat, et al.
Publicado: (2018) -
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis
por: Ticau, Simina, et al.
Publicado: (2021) -
Evidence of Concurrent Light Chain and Transthyretin Cardiac Amyloidosis in 2 Patients
por: Donnelly, Joseph P., et al.
Publicado: (2020) -
Prevalence and Treatment of Arrhythmias in Patients With Transthyretin and Light-Chain Cardiac Amyloidosis
por: Miyamoto, Masakazu, et al.
Publicado: (2023)